PROTHENA CORPORATION PUBLIC LIMITED COMPANY Research and Development Expense
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Research and Development Expense of $8.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY research and development expense for the quarter ending 2026-06-30 was $8.80M, a 78.29% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY research and development expense for the quarter ending 2026-03-31 was $12.63M, a 75.15% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY research and development expense for the quarter ending 2025-12-31 was $14.59M, a 70.93% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY research and development expense for the quarter ending 2025-09-30 was $28.94M, a 42.95% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY research and development expense for fiscal 2025 was $134.85M, a 39.40% decline from fiscal 2024.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY research and development expense for fiscal 2024 was $222.52M, a 0.88% increase from fiscal 2023.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY research and development expense for fiscal 2023 was $220.57M, a 62.71% increase from fiscal 2022.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY research and development expense for fiscal 2022 was $135.56M, a 64.75% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.80M 10-Q · filed 2026-08-06 | $21.43M 10-Q · filed 2026-08-06 | $36.01M derived: sum of 3 quarters · filed 2026-08-06 | $64.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $12.63M 10-Q · filed 2026-05-07 | $27.21M derived: sum of 2 quarters · filed 2026-05-07 | $56.15M derived: sum of 3 quarters · filed 2026-05-07 | $96.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $14.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $43.52M derived: sum of 2 quarters · filed 2026-02-27 | $84.04M derived: sum of 3 quarters · filed 2026-08-06 | $134.85M 10-K · filed 2026-02-27 |
| 2025-09-30 | $28.94M 10-Q · filed 2025-11-06 | $69.45M derived: sum of 2 quarters · filed 2026-08-06 | $120.27M 10-Q · filed 2025-11-06 | $170.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $40.52M 10-Q · filed 2026-08-06 | $91.33M 10-Q · filed 2026-08-06 | $141.50M derived: sum of 3 quarters · filed 2026-08-06 | $192.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $50.81M 10-Q · filed 2026-05-07 | $100.98M derived: sum of 2 quarters · filed 2026-05-07 | $151.71M derived: sum of 3 quarters · filed 2026-05-07 | $209.22M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $50.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $100.89M derived: sum of 2 quarters · filed 2026-02-27 | $158.41M derived: sum of 3 quarters · filed 2026-02-27 | $222.52M 10-K · filed 2026-02-27 |
| 2024-09-30 | $50.72M 10-Q · filed 2025-11-06 | $108.23M derived: sum of 2 quarters · filed 2025-11-06 | $172.35M 10-Q · filed 2025-11-06 | $234.24M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $57.51M 10-Q · filed 2025-08-04 | $121.62M 10-Q · filed 2025-08-04 | $183.51M derived: sum of 3 quarters · filed 2026-02-27 | $241.43M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $64.11M 10-Q · filed 2025-05-08 | $126.00M derived: sum of 2 quarters · filed 2026-02-27 | $183.92M derived: sum of 3 quarters · filed 2026-02-27 | $239.93M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $61.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $119.80M derived: sum of 2 quarters · filed 2026-02-27 | $175.81M derived: sum of 3 quarters · filed 2026-02-27 | $220.57M 10-K · filed 2026-02-27 |
| 2023-09-30 | $57.91M 10-Q · filed 2024-11-12 | $113.92M derived: sum of 2 quarters · filed 2024-11-12 | $158.68M 10-Q · filed 2024-11-12 | $195.55M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $56.01M 10-Q · filed 2024-08-08 | $100.77M 10-Q · filed 2024-08-08 | $137.64M derived: sum of 3 quarters · filed 2025-02-27 | $177.50M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $44.76M 10-Q · filed 2024-05-08 | $81.63M derived: sum of 2 quarters · filed 2025-02-27 | $121.49M derived: sum of 3 quarters · filed 2025-02-27 | $153.06M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $36.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $76.73M derived: sum of 2 quarters · filed 2025-02-27 | $108.30M derived: sum of 3 quarters · filed 2025-02-27 | $135.56M 10-K · filed 2025-02-27 |
| 2022-09-30 | $39.86M 10-Q · filed 2023-11-02 | $71.43M derived: sum of 2 quarters · filed 2023-11-02 | $98.69M 10-Q · filed 2023-11-02 | $120.75M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $31.57M 10-Q · filed 2023-08-03 | $58.83M 10-Q · filed 2023-08-03 | $80.89M derived: sum of 3 quarters · filed 2024-02-22 | $98.88M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $27.26M 10-Q · filed 2023-05-04 | $49.32M derived: sum of 2 quarters · filed 2024-02-22 | $67.31M derived: sum of 3 quarters · filed 2024-02-22 | $88.40M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $22.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $40.05M derived: sum of 2 quarters · filed 2024-02-22 | $61.14M derived: sum of 3 quarters · filed 2024-02-22 | $82.28M 10-K · filed 2024-02-22 |
| 2021-09-30 | $17.99M 10-Q · filed 2022-11-03 | $39.08M derived: sum of 2 quarters · filed 2022-11-03 | $60.23M 10-Q · filed 2022-11-03 | $80.99M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $21.09M 10-Q · filed 2022-08-08 | $42.23M 10-Q · filed 2022-08-08 | $62.99M derived: sum of 3 quarters · filed 2023-02-28 | $84.60M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $21.14M 10-Q · filed 2022-05-05 | $41.90M derived: sum of 2 quarters · filed 2023-02-28 | $63.51M derived: sum of 3 quarters · filed 2023-02-28 | $80.78M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $20.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $42.37M derived: sum of 2 quarters · filed 2023-02-28 | $59.64M derived: sum of 3 quarters · filed 2023-02-28 | $74.88M 10-K · filed 2023-02-28 |
| 2020-09-30 | $21.61M 10-Q · filed 2021-11-04 | $38.88M derived: sum of 2 quarters · filed 2021-11-04 | $54.12M 10-Q · filed 2021-11-04 | $69.59M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $17.27M 10-Q · filed 2021-08-05 | $32.52M 10-Q · filed 2021-08-05 | $47.99M derived: sum of 3 quarters · filed 2022-02-25 | $60.48M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $15.25M 10-Q · filed 2021-05-11 | $30.72M derived: sum of 2 quarters · filed 2022-02-25 | $43.20M derived: sum of 3 quarters · filed 2022-02-25 | $52.79M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $15.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $27.96M derived: sum of 2 quarters · filed 2022-02-25 | $37.54M derived: sum of 3 quarters · filed 2022-02-25 | $50.84M 10-K · filed 2022-02-25 |
| 2019-09-30 | $12.49M 10-Q · filed 2020-11-04 | $22.07M derived: sum of 2 quarters · filed 2020-11-04 | $35.37M 10-Q · filed 2020-11-04 | $51.88M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $9.58M 10-Q · filed 2020-08-06 | $22.88M 10-Q · filed 2020-08-06 | $39.39M derived: sum of 3 quarters · filed 2021-02-26 | $57.90M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $13.30M 10-Q · filed 2020-05-06 | $29.81M derived: sum of 2 quarters · filed 2021-02-26 | $48.32M derived: sum of 3 quarters · filed 2021-02-26 | $79.77M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $16.51M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $35.02M derived: sum of 2 quarters · filed 2021-02-26 | $66.48M derived: sum of 3 quarters · filed 2021-02-26 | $101.18M 10-K · filed 2021-02-26 |
| 2018-09-30 | $18.52M 10-Q · filed 2019-11-05 | $49.97M derived: sum of 2 quarters · filed 2019-11-05 | $84.67M 10-Q · filed 2019-11-05 | $118.17M derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-06-30 | $31.45M 10-Q · filed 2019-08-06 | $66.16M 10-Q · filed 2019-08-06 | $99.66M derived: sum of 3 quarters · filed 2020-03-03 | $140.97M derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-03-31 | $34.71M 10-Q · filed 2019-05-07 | $68.21M derived: sum of 2 quarters · filed 2020-03-03 | $109.52M derived: sum of 3 quarters · filed 2020-03-03 | $143.56M derived: sum of 4 quarters · filed 2020-03-03 |
| 2017-12-31 | $33.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $74.82M derived: sum of 2 quarters · filed 2020-03-03 | $108.85M derived: sum of 3 quarters · filed 2020-03-03 | $134.55M 10-K · filed 2020-03-03 |
| 2017-09-30 | $41.31M 10-Q · filed 2018-11-06 | $75.35M derived: sum of 2 quarters · filed 2018-11-06 | $101.05M 10-Q · filed 2018-11-06 | $140.89M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-06-30 | $34.03M 10-Q · filed 2018-08-07 | $59.73M 10-Q · filed 2018-08-07 | $99.57M derived: sum of 3 quarters · filed 2019-03-15 | $126.41M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-03-31 | $25.70M 10-Q · filed 2018-05-09 | $65.54M derived: sum of 2 quarters · filed 2019-03-15 | $92.38M derived: sum of 3 quarters · filed 2019-03-15 | $124.74M derived: sum of 4 quarters · filed 2019-03-15 |
| 2016-12-31 | $39.84M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $66.68M derived: sum of 2 quarters · filed 2019-03-15 | $99.04M derived: sum of 3 quarters · filed 2019-03-15 | $119.53M 10-K · filed 2019-03-15 |
| 2016-09-30 | $26.84M 10-Q · filed 2017-11-07 | $59.20M derived: sum of 2 quarters · filed 2017-11-07 | $79.69M 10-Q · filed 2017-11-07 | $97.58M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-06-30 | $32.36M 10-Q · filed 2017-08-09 | $52.85M 10-Q · filed 2017-08-09 | $70.74M derived: sum of 3 quarters · filed 2018-02-26 | $87.93M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-03-31 | $20.49M 10-Q · filed 2017-05-09 | $38.38M derived: sum of 2 quarters · filed 2018-02-26 | $55.57M derived: sum of 3 quarters · filed 2018-02-26 | $68.36M derived: sum of 4 quarters · filed 2018-02-26 |
| 2015-12-31 | $17.89M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $35.08M derived: sum of 2 quarters · filed 2018-02-26 | $47.87M derived: sum of 3 quarters · filed 2018-02-26 | $58.44M 10-K · filed 2018-02-26 |
| 2015-09-30 | $17.18M 10-Q · filed 2016-11-02 | $29.98M derived: sum of 2 quarters · filed 2016-11-02 | $40.55M 10-Q · filed 2016-11-02 | $50.66M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-06-30 | $12.79M 10-Q · filed 2016-08-02 | $23.36M 10-Q · filed 2016-08-02 | $33.47M derived: sum of 3 quarters · filed 2017-02-27 | $43.86M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-03-31 | $10.57M 10-Q · filed 2016-05-04 | $20.68M derived: sum of 2 quarters · filed 2017-02-27 | $31.07M derived: sum of 3 quarters · filed 2017-02-27 | $39.68M derived: sum of 4 quarters · filed 2017-02-27 |
| 2014-12-31 | $10.11M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $20.50M derived: sum of 2 quarters · filed 2017-02-27 | $29.11M derived: sum of 3 quarters · filed 2017-02-27 | $38.45M 10-K · filed 2017-02-27 |
| 2014-09-30 | $10.39M 10-Q · filed 2015-11-02 | $19.00M derived: sum of 2 quarters · filed 2015-11-02 | $28.34M 10-Q · filed 2015-11-02 | $33.95M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $8.62M 10-Q · filed 2015-08-05 | $17.96M 10-Q · filed 2015-08-05 | $23.56M derived: sum of 3 quarters · filed 2016-02-25 | $29.91M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | $9.34M 10-Q · filed 2015-05-06 | $14.94M derived: sum of 2 quarters · filed 2016-02-25 | $21.29M derived: sum of 3 quarters · filed 2016-02-25 | $29.44M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | $5.60M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $11.95M derived: sum of 2 quarters · filed 2016-02-25 | $20.09M derived: sum of 3 quarters · filed 2016-02-25 | $26.05M 10-K · filed 2016-02-25 |
| 2013-09-30 | $6.35M 10-Q · filed 2014-11-04 | $14.49M derived: sum of 2 quarters · filed 2014-11-04 | $20.45M 10-Q · filed 2014-11-04 | $30.29M derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-06-30 | $8.15M 10-Q · filed 2014-08-05 | $14.10M 10-Q · filed 2014-08-05 | $23.94M derived: sum of 3 quarters · filed 2015-03-13 | $31.47M derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-03-31 | $5.96M 10-Q · filed 2014-05-05 | $15.79M derived: sum of 2 quarters · filed 2015-03-13 | $23.32M derived: sum of 3 quarters · filed 2015-03-13 | $31.34M derived: sum of 4 quarters · filed 2015-03-13 |
| 2012-12-31 | $9.83M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $17.36M derived: sum of 2 quarters · filed 2015-03-13 | $25.38M derived: sum of 3 quarters · filed 2015-03-13 | $34.14M 10-K · filed 2015-03-13 |
| 2012-09-30 | $7.53M 10-Q · filed 2013-11-12 | $15.55M derived: sum of 2 quarters · filed 2013-11-12 | $24.31M 10-Q · filed 2013-11-12 | |
| 2012-06-30 | $8.02M 10-Q · filed 2013-08-13 | $16.78M 10-Q · filed 2013-08-13 | ||
| 2012-03-31 | $8.76M 10-Q · filed 2013-05-15 | |||
| 2011-12-31 | $24.17M 10-K · filed 2014-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |